ENSCW Ensysce Biosciences, Inc.

BEARISH Impact: 7/10 8-K
Horizon weeks Filed May 22, 2026 Processed 18d 7h ago SEC 0001493152-26-025061
8-K context-dependent: Items 3.01

Price Chart

Loading chart...

Executive Summary

Ensysce Biosciences received a Nasdaq delisting notice on May 21, 2026 for failing to meet the $2.5M stockholders' equity requirement as of March 31, 2026. The company has 45 days (by July 6, 2026) to submit a compliance plan, with a possible 180-day extension. Failure to regain compliance will result in delisting from Nasdaq.

Actionable Insight

Monitor the compliance plan submission by July 6, 2026. If the plan is rejected or the company fails to regain compliance within the extension period, warrants will likely be delisted from Nasdaq and trade over-the-counter with minimal liquidity. Given the small market cap and early-stage nature, a capital raise or reverse split may be attempted to restore equity — watch for related filings.

Key Facts

  • Nasdaq delisting notice received May 21, 2026 for non-compliance with $2.5M stockholders' equity requirement (Rule 5550(b)(1))
  • Deadline to submit compliance plan: July 6, 2026 (45 days from notice)
  • If plan accepted, extension up to 180 days from May 21, 2026 to regain compliance
  • If plan rejected, company may appeal to Nasdaq Hearings Panel
  • No assurance that plan will be accepted or compliance can be regained
  • Ticker ENSCW is a warrant, not common stock; common stock (ENSC) trades on Nasdaq

Financial Impact

Delisting risk is binary; if delisted, warrants (ENSCW) lose exchange listing and liquidity severely dries up

stockholders_equitylisting_statusliquidity

Risk Factors

  • Delisting from Nasdaq would severely reduce liquidity and institutional ownership
  • Company may need to raise dilutive capital at distressed levels to restore equity compliance
  • If appeal fails, warrants (ENSCW) could become worthless or trade at pennies
  • Uncertainty around ability to regain compliance within timeline

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-025061
Document: 0001493152-26-025061-index-headers.html0001493152-26-025061
Document: 0001493152-26-025061-index.html0001493152-26-025061
Document: 0001493152-26-025061.txt0001493152-26-025061
5 reports for ENSCW
Performance horizon
Filters
Rows
Reports for ENSCW — sortable, filterable
Type Now
Jun 4, 2026
5d ago
S-3
BEARISH ★ 6/10
awaiting T+20
May 22, 2026
18d ago
8-K
BEARISH ★ 7/10
awaiting T+20
May 15, 2026
25d ago
8-K
BEARISH ★ 7/10
awaiting T+20
Apr 3, 2026
9w ago
8-K
NEUTRAL ★ 3/10
awaiting T+20
Mar 30, 2026
10w ago
8-K
NEUTRAL ★ 4/10
awaiting T+20
Showing 5 of 5

US Market Status

Market Closed — Opens in 8h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access